Mavefund EN
Penumbra Inc logo

Penumbra Inc

PEN
Letzter Kurs (USD) US$321.68
Marktkapitalisierung (USD) US$12.6b
Kursänderung 12 Monate 18.30%
Loading the 12-month Mave Thesis and 1-month news signal

Start Heute Aktien Watchlist

Penumbra Inc Überblick

Branche: Medical Devices

Sektor: Healthcare

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such

Research-Überblick

Letztes Berichtsdatum 2026-07-30

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Penumbra Inc (PEN): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
PEN · NYSE · MIC XNYS
Land
United States
Handelswährung
USD
Branche
Medical Devices
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-07-30
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Penumbra Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Jul 30, 2026

Quarterly result summary

Revenue was $390M (reported). Net income/share was $0.88. Income from operations was $41M.

Revenue $390M reported
Net income/share $0.88 reported
Income from operations $41M reported
Operating income $41M +1% YoY

Was sich verändert hat

  • Revenue reported to $390M.
  • Operating income +1% YoY to $41M.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 2.00/5
Penumbra Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

Eigenkapitalrendite

Score 3.12/5
Penumbra Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Penumbra Inc PEN US$12.6b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 3.40/5
Penumbra Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Penumbra Inc PEN US$12.6b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

Verschuldung

Score 3.05/5
Penumbra Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Penumbra Inc PEN US$12.6b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Penumbra Inc logo

Penumbra Inc

US$321.68

US$85.68

-73.4% vs price

US$12.6b

-1.08%

18.30%